Brief: Aptose Says CG-806 Safely And Durably Suppressed Tumor Growth In Preclinical Models
14/06/2019 12:18
June 14 (Reuters) - Aptose Biosciences Inc APS.TO :
* APTOSE PRESENTS NEW PRECLINICAL DATA FOR CG-806 AT THE
24TH
CONGRESS OF THE EUROPEAN HEMATOLOGY ASSOCIATION
* APTOSE BIOSCIENCES INC - CG-806 SAFELY AND DURABLY
SUPPRESSED
TUMOR GROWTH IN PRECLINICAL MODELS
Source text for Eikon: ID:nGNX29YgLG
Further company coverage: APS.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aptose Biosciences
See all newsBrief: Aptose Biosciences Says Closing Of Arrangement With Hanmi Pharmaceutical Further Delayed
Brief: Aptose Reports First Quarter 2026 Results
Brief: Leading Independent Proxy Advisory Firm Glass Lewis Endorses Aptose Plan Of Arrangement
Brief: Leading Independent Proxy Advisory Firm Iss Recommends Aptose Biosciences Shareholders Vote “For” Proposed Plan Of Arrangement With Hanmi Pharmaceutical
Brief: Aptose Biosciences Announces Amendment To Arrangement Agreement And Details Of Shareholders Meeting